Csl Behring Gmbh

Basf Se Corporation

Csl Limited

The General Hospital Corporation

Basf Agro B.v.

Universitât Bern

Westfaelische Wilhelms-universitaet Muenster

Julius-maximilians-universitaet Wuerzburg

Universitaet Bern

Basf Corporation

Westfalische Wilhelms-universität Münster

Csl Behring Lengnau Ag

Marc Nolte

Con Panousis

Andrew Donald Nash

Michael Wilson

Veronika Rayzman

Stefan Schmidbauer

Gerhard Schnabel

Gerhard Dickneite

Stefan Schulte

Richard Roger Evans

Paul Klingelhoefer

Ingo Pragst

Christoph Kleinschnitz

Gerd Haderlein

Gerd Kraemer

Steven Joseph Bowe

Sophie Vogel

Sylvia Miescher

Terrance Cannan

Kevin Huyghe

Ralph Weissleder

Matthias Bratz

Karl-Heinrich Schneider

Rolf Spirig

Stefan Zeitler

Arend Jouke Kingma

Wen Xu

Claude Taranta

Sonia J Patterson

Sophie Maitro-Vogel

Chad Brommer

Charles W Finch

Murat Mertoglu

Ouidad Benlahmar

Maarten Staal

Clark Klein

Thomas Kröhl

Thomas Bork

Michael D Capracotta

Thomas Kroehl

Wolfgang Meier

Brent Steven McKenzie

Tatjana Levy

Henning Urch

Robert Huber

Kristin Klappach

Karl Häberle

Bernhard Nieswandt

Matthias P Nahrendorf

Silke Zeyer

Birgit Blanz

Claudia Duehrkop-Sisewitsch

Robert Rieben

Guido Stoll

Matthias Pfenning

Diana Franz

Malgorzata Wygrecka

Tiffany Hennessey

Stefan Bechtel

Sven Meuth

Diana Westfalia Moran Puente

Steffen Henkes

Laura L Brasher

Klaus Kolb

Siegfried Doerr

Mariano Ignacio Etcheverry

Gerhard Genari

Annett Kuehn

John Frihauf

Walter Thomas

Raffaello Zito

Christoph Randt

Randall Evan Gold

Bernd Stockburger

Gunter Niesar

Christine Voigt

John Roberts

Rolf Rehkugler

Anna-Leena Sirén

Christiane Albert-weissenberger

Sarah Hopp-kraemer

Juri Mogilewski

Amandine Michel

Kerstin Goebel

Christian Kepes

Lydia Ludwig

Shilpa Puli

Clark D Klein

Antonio Parenti

Michael Merk

Terrance M Cannan

Peter Welter

Brent Mckenzie

Christiane Albert-Weissenberger

Sarah Hopp-Kraemer

Anna-Leena Siren

The present invention relates to microcapsules comprising a core, wherein the core comprises cinmethylin, and a polyurea shell, wherein the shell comprises a polyaddition product of diphenylmethane diisocyanate or an oligomer thereof and at least one amine having at least two primary amino groups; to a composition comprising such microcapsules; to a method for preparing such microcapsules or such a composition; to a composition obtainable by said preparation method; and to the use of such microcapsules or compositions for controlling undesired vegetation.

Microcapsules comprising cinmethyln in the core and a polyurea derived from diphenylmethane diisocyanate or an oligomer thereof

The present invention relates to the use of a direct Factor XII (FXII) inhibitor in the treatment of a neurotraumatic disorder resulting from a traumatic injury of the brain (traumatic brain injury, TBI) or the spinal cord (spinal cord injury, SCI).

Therapy using a factor XII inhibitor in a neurotraumatic disorder

The invention relates to an inhibitor of Factor XII (FXII) for use in treating or preventing chronic kidney disease, renal fibrosis, glomerulosclerosis, renal scarring, ischemia/reperfusion injury in native or transplant kidneys and/or acute kidney injury, a kit for use in treating or preventing chronic kidney disease, renal fibrosis, glomerulosclerosis, renal scarring, ischemia/reperfusion injury in native or transplant kidneys, acute kidney injury, renal fibrosis as a result of rejection of a kidney transplant/allograft, and/or fibrosis of a kidney transplant/allograft as a result of rejection or recurrent underlying disease comprising one inhibitor of Factor XII, and an anti-Factor XII (FXII) antibody or antigen binding fragment thereof for use in treating or preventing chronic kidney disease, renal fibrosis, glomerulosclerosis, renal scarring, ischemia/reperfusion injury in native or transplant kidneys and/or acute kidney injury comprising one inhibitor of Factor XII.

Use of a FXIIa-inhibitor in the treatment of renal fibrosis and/or chronic kidney disease

The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.

Methods of administering inhibitory anti-factor XII/XIIa monoclonal antibodies

The present invention relates to a portable spraying device () for discharging a fluid, in particular an agricultural formulation, having a container () for holding the fluid, a pump (), which is in fluid connection with the container (), for pumping the fluid out of the container (), a spray gun (), which comprises a spray opening () and an electrically controllable application valve () for opening and closing a passage to the spray opening (), an application line (), which establishes a fluid connection between the pump () and the spray gun (). The spraying device () according to the invention is distinguished by a pressure sensor (), which is arranged in the application line (), for detecting the fluid pressure in the application line (), and an electric control device (), which is coupled to the application valve () and the pressure sensor () in terms of data transmission, by means of which device an electric control signal for opening the application valve () for a certain predetermined time interval and for closing the application valve () on expiry of the time interval can be produced in accordance with the fluid pressure detected by means of the pressure sensor (), with the result that a defined volume of the fluid is discharged via the spray opening ().

Portable spray device

The present invention relates to a contact activation system inhibitor, preferably a C1INH, for use in the treatment and/or prevention of remote ischemia-reperfusion injury (IRI), comprising administering the contact activation system inhibitory to an individual.

Treatment and prevention of remote ischemia-reperfusion injury

Methods of administering inhibitory anti-factor XII/XIIA monoclonal antibodies

An inhibitor of FXII/FXIIa for the prevention of the formation and/or stabilization of thrombi during and/or after a medical procedure performed on a human or animal subject comprising contacting blood of said human or animal subject with artificial surfaces, wherein said inhibitor of FXII/FXIIa is administered before and/or during and/or after said medical procedure.

Factor XII inhibitors for the administration with medical procedures comprising contact with artificial surfaces

This application relates to neurological inflammatory diseases, such as multiple sclerosis, and to methods of administering a Factor XII inhibitor to prevent, treat, or otherwise ameliorate the effects of a neurological inflammatory disease, such as multiple sclerosis. Agents and pharmaceutical compositions comprising agents which inhibit the activity of FXII are also provided.

Factor XII inhibitors for the treatment of neurological inflammatory disorders

Nucleic acids encoding inhibitory anti-factor XII/XIIa monoclonal antibodies

A composition and a method of preparing the composition are provided herein. The composition comprises an active substance and a polymeric additive comprising at least one unit represented by the formula (I): wherein each R is independently selected from the group of a hydrogen atom, an alkyl group, an aryl group, and combinations thereof; and Z comprises at least 10 units represented by the formula (II): wherein each Ris independently selected from the group of a hydrogen atom, an alkyl group, an aryl group, a carbonyl group, a hydroxyl group, an ether group, and combinations thereof and Ris a C-Chydrocarbon group. The polymeric additive further comprising at least one unit represented by the formula (III):A&#x2003;&#x2003;(III)wherein A is an alkyleneoxy group having from 2 to 10 carbon atoms.

Composition comprising an active substance and a polyalkyleneoxide vinylester graft polymer

The present invention relates to a composition comprising a pesticide, a surfactant and an alkoxylate. Moreover, the invention relates to a concentrate comprising the surfactant and the alkoxylate; and to a process for preparing the composition by bringing into contact the concentrate and a pesticide; or by bringing into contact the pesticide, the surfactant and the alkoxylate; and to the use of the surfactant by addition to a mixture comprising the pesticide and the alkoxylate. The invention furthermore relates to a method of controlling phytopathogenic fungi and/or undesired vegetation and/or undesired insect or mite attack and/or for regulating the growth of plants, wherein the composition is allowed to act on the respective pests, their environment or the plants to be protected from the respective pest, on the soil and/or on undesirable plants and/or the crop plants and/or their environment. Furthermore, the invention relates to seed comprising the composition.

Composition comprising a pesticide, a surfactant and an alkoxylate of 2-propyheptylamine

Silent brain ischemia (SBI) or ischemia of other organs can result from an embolism that is introduced into the arterial system during a medical procedure. The application provides a method of administering a FXII inhibitor in a patient receiving a medical procedure and animal models useful for studying ischemia including SBI and ischemia in other organs, and for evaluating candidate therapeutics.

Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs

Growing community of inventors

Marburg, Germany

Marc Nolte